Research programme: stem cell therapeutics - Histostem

Drug Profile

Research programme: stem cell therapeutics - Histostem

Alternative Names: Cirrhosis HMScs - Histochem

Latest Information Update: 10 Mar 2011

Price : $50

At a glance

  • Originator Histostem
  • Class
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Preclinical Alopecia; Diabetes mellitus; Liver cirrhosis; Multiple sclerosis; Osteonecrosis; Osteoporosis; Spinal cord injuries; Thromboangiitis obliterans
  • Discontinued Alzheimer's disease

Most Recent Events

  • 10 Mar 2011 Preclinical development is ongoing in South Korea
  • 24 Feb 2010 Pharmacodynamics data from a preclinical trial in Cirrhosis released by Histostem
  • 27 Mar 2006 Preclinical trials in Spinal cord injuries in South Korea (Parenteral, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top